Diflunisal is asalicylic acid derivative with analgesic and anti-inflammatory activity.[2] It was developed byMerck Sharp & Dohme in 1971, as MK647, after showing promise in a research project studying more potent chemical analogs ofaspirin.[3] It was first sold under the brand nameDolobid, marketed byMerck & Co., but generic versions are now widely available. It is classed as anonsteroidal anti-inflammatory drug (NSAID) and is available in 250 mg and 500 mg tablets.
Like all NSAIDs, diflunisal acts by inhibiting the production ofprostaglandins,[4] hormones which are involved in inflammation and pain. Diflunisal also has anantipyretic effect, but this is not a recommended use of the drug.[5]
It has been found to inhibitp300 andCREB-binding protein (CBP), which are epigenetic regulators that control the levels of proteins that cause inflammation or are involved in cell growth.[6]
It has been reported that diflunisal has some antibacterial activity in vitro against Francisella tularensis live vaccine strain (LVS).[7]
Though diflunisal has an onset time of 1 hour, and maximumanalgesia at 2 to 3 hours, the plasma levels of diflunisal will not be steady until repeated doses are taken.[5] The long plasma half-life is a distinctive feature of diflunisal in comparison to similar drugs. To increase the rate at which the diflunisal plasma levels become steady, a loading dose is usually used. It is primarily used to treat symptoms ofarthritis,[8] and for acute pain following oral surgery, especially removal ofwisdom teeth.[9]
Effectiveness of diflunisal is similar to other NSAIDs, but the duration of action is twelve hours or more. This means fewer doses per day are required for chronic administration. In acute use, it is popular in dentistry when a single dose after oral surgery can maintain analgesia until the patient is asleep that night.
Both diflunisal[10][11] and several of its analogues[12] have been shown to be inhibitors oftransthyretin-related hereditary amyloidosis, a disease which currently has few treatment options.Phase I trials have shown the drug to be well tolerated,[13] with a small Phase II trial (double-blind, placebo-controlled, 130 patients for 2 years) in 2013 showing a reduced rate of disease progression and preserved quality of life.[14] However a significantly larger Phase III trial would be needed to prove the drugs effectiveness for treating this condition.
In October 2020, the U.S.Food and Drug Administration (FDA) required thedrug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[15][16] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[15][16]
The inhibition of prostaglandins has the effect of decreasing the protection given to the stomach from its own acid. Like all NSAIDS, this leads to an increased risk of stomach ulcers, and their complications, with long-term use. Elderly users of diflunisal are at greater risk for serious GI events.
Increased risk of GI events including bleeding, ulceration, and stomach or intestine perforation.
Deaths that have occurred from diflunisal usually involved mixed drugs and or extremely high dosage. The oralLD50 is 500 mg/kg. Symptoms of overdose include coma,tachycardia, stupor, and vomiting. The lowest dose without the presence of other medicines which caused death was 15 grams. Mixed with other medicines, a death at 7.5 grams has also occurred. Diflunisal usually comes in 250 or 500 mg, making it relatively hard to overdose by accident.
^Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS (February 1980). "Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis".Drugs.19 (2):84–106.doi:10.2165/00003495-198019020-00002.PMID6988202.S2CID24191409.
^Lawton GM, Chapman PJ (August 1993). "Diflunisal--a long-acting non-steroidal anti-inflammatory drug. A review of its pharmacology and effectiveness in management of postoperative dental pain".Australian Dental Journal.38 (4):265–71.doi:10.1111/j.1834-7819.1993.tb05494.x.PMID8216032.
^Tojo K, Sekijima Y, Kelly JW, Ikeda S (December 2006). "Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis".Neuroscience Research.56 (4):441–9.doi:10.1016/j.neures.2006.08.014.PMID17028027.S2CID42504073.
^Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW (January 2004). "Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis".Journal of Medicinal Chemistry.47 (2):355–74.doi:10.1021/jm030347n.PMID14711308.
^Berk JL, Suhr OB, Sekijima Y, Yamashita T, Heneghan M, Zeldenrust SR, et al. (June 2012). "The Diflunisal Trial: study accrual and drug tolerance".Amyloid.19 (Suppl 1):37–8.doi:10.3109/13506129.2012.678509.PMID22551208.S2CID40303434.
This article incorporates text from this source, which is in thepublic domain.
